Librium is the brand name most people still use for chlordiazepoxide, one of the oldest benzodiazepines on the market. Prescribers reach for it mainly for short term anxiety relief and, more commonly today, for managing acute alcohol withdrawal in a monitored setting. Because chlordiazepoxide is a long acting benzodiazepine that breaks down into other benzodiazepine metabolites the body keeps producing for days after the last dose, it is not a borderline or questionable result on a standard benzodiazepine (BZO) drug test. It is a true positive, and employers, clinics, and treatment programs need to understand why, and what documentation closes the loop.
What Librium actually is
Chlordiazepoxide hydrochloride is listed as a Schedule IV controlled substance under the federal Controlled Substances Act, in the same tier as diazepam (Valium), lorazepam (Ativan), and clonazepam (Klonopin), according to the Drug Enforcement Administration's schedule published in the Code of Federal Regulations, Title 21, Part 1308. The current current prescribing information, available through the National Library of Medicine's DailyMed label for chlordiazepoxide hydrochloride capsules, lists approved uses for anxiety disorders, short term relief of anxiety symptoms, and management of the acute agitation, tremor, and impending delirium tremens that can accompany alcohol withdrawal. It is not FDA cleared for recreational use, and like other benzodiazepines it carries dependence and withdrawal risk with extended use, which is a decision between a patient and their prescriber, not something this article weighs in on.
How the body processes chlordiazepoxide
Chlordiazepoxide itself has a moderate half life, but it does not leave the body as chlordiazepoxide. The liver converts it first to desmethylchlordiazepoxide and demoxepam, and then to nordiazepam, also called desmethyldiazepam. Nordiazepam is the same active metabolite produced by diazepam, and it continues to convert into oxazepam, and in some pathways into temazepam. The National Institutes of Health's StatPearls chapter on benzodiazepine toxicity describes this shared metabolic pathway across the older benzodiazepine class, and the consumer drug monograph on MedlinePlus confirms the same clinical profile and long elimination half life for the active metabolites. Nordiazepam in particular has a much longer half life than the parent drug, commonly cited in the days range rather than hours, which is the reason chlordiazepoxide use shows up on urine screens well after the dose that caused it.
Why this is a true BZO positive, not a false positive
Rapid immunoassay cups and dip cards built around a benzodiazepine (BZO) panel are designed to detect the oxazepam type metabolites that most prescription benzodiazepines, including chlordiazepoxide, diazepam, and temazepam, break down into. Because chlordiazepoxide's metabolic pathway runs directly through nordiazepam and oxazepam, a person taking Librium as prescribed, or tapering off it in a withdrawal protocol, is expected to screen positive on the BZO panel. That is detection working correctly, not an interference problem. This is a meaningfully different situation from a false positive drug, where a screening immunoassay cross reacts with a chemical structure that only resembles the target drug. There is limited to no published cross reactivity evidence suggesting chlordiazepoxide triggers a benzodiazepine positive through some unrelated mechanism. It triggers the panel because its metabolites are the panel's actual target.
Because immunoassay screens report a class level result and cannot distinguish chlordiazepoxide from diazepam, temazepam, or other benzodiazepines that share the nordiazepam or oxazepam pathway, any screen positive benzodiazepine result that matters for an employment or program decision should go to gas chromatography mass spectrometry (GC/MS) or liquid chromatography tandem mass spectrometry (LC/MS) confirmation. Confirmation testing identifies the specific analytes present and their approximate concentrations, which is the information a medical review officer actually needs to evaluate the result against a prescription.
Detection window after a taper
Alcohol withdrawal protocols typically use chlordiazepoxide on a short, front loaded or symptom triggered schedule rather than a steady daily dose for months, but the detection window is still driven by the metabolites, not by how many days the taper lasted. Because nordiazepam accumulates with repeat dosing and clears slowly, a multi day inpatient taper can leave a longer urine detection window than a single dose would suggest, and the exact window varies by individual metabolism, dose, kidney and liver function, and hydration. Programs should not try to predict an exact number of clean days from a taper schedule; that is a question for the prescribing clinician and, if relevant to an employment decision, the MRO, not something to estimate from a chart. Oral fluid testing generally reflects more recent use with a shorter window than urine, which is one reason some treatment programs pair the two matrices rather than relying on one.
Benzodiazepines compared by elimination profile
| Medication | Common brand | Parent half life | Key active metabolite | General elimination category |
|---|---|---|---|---|
| Chlordiazepoxide | Librium | Moderate (hours to about a day) | Nordiazepam (desmethyldiazepam) | Long acting |
| Diazepam | Valium | Long | Nordiazepam (desmethyldiazepam) | Long acting |
| Clonazepam | Klonopin | Long | 7 amino clonazepam (minor, inactive for screening purposes) | Long acting |
| Temazepam | Restoril | Intermediate | Oxazepam (minor pathway) | Intermediate acting |
| Lorazepam | Ativan | Intermediate | Lorazepam glucuronide (direct conjugate, no active metabolite) | Intermediate acting |
| Oxazepam | Serax | Short to intermediate | None, excreted largely unchanged as a glucuronide | Short to intermediate acting |
| Alprazolam | Xanax | Short to intermediate | Alpha hydroxyalprazolam (minor) | Short acting |
The pattern to notice is that chlordiazepoxide sits in the same long acting, nordiazepam producing family as diazepam, which is why it tends to carry one of the longer urine detection windows among commonly prescribed benzodiazepines, consistent with the elimination half life data summarized in the NIH Bookshelf chapter on benzodiazepine toxicity cited above. Exact day counts vary by person and are not something a screening program should state as a fixed number.
The medical review officer process for treatment program patients
Any non negotiated benzodiazepine positive under a DOT regulated testing program, and most non regulated workplace programs that follow the same model, routes through a certifying scientist and then a medical review officer rather than straight to an employer. Under the federal procedures at 49 CFR Part 40, Subpart G, the MRO contacts the individual, asks about current prescriptions, and may contact the prescribing clinician to verify that the medication was legitimately prescribed and that the dose is consistent with a legitimate medical explanation before reporting a result as verified positive or negative. For someone in an alcohol withdrawal program, that verification should include the admitting facility or prescribing physician's documentation of the chlordiazepoxide taper, since a short inpatient course is a normal, clinically supervised use of the drug rather than an irregularity. Programs built on the Substance Abuse and Mental Health Services Administration model described at SAMHSA's drug free workplace program page follow the same logic: a verified prescription with a legitimate medical explanation is not treated as a policy violation, but the documentation has to exist and has to reach the MRO, not just sit in the person's medicine cabinet.
What this means for employers and programs
If a benzodiazepine panel comes back positive, the right next step is confirmation testing plus the standard MRO prescription review, not a snap judgment. Chlordiazepoxide is not a drug that should be excluded from a BZO panel on the theory that it will not show up; it is squarely inside the class the panel is built to catch, through metabolites it shares with other prescribed benzodiazepines. Programs that want to compare panel formats, including cups, dip cards, and oral fluid devices that include a BZO line, can review the options in the drug test cup collection. Clinics, treatment programs, and distributors buying panels in volume for an outpatient or detox setting can also review case pricing and panel configurations through the wholesale portal.
Frequently asked questions
Does Librium show up as a benzodiazepine on a drug test?
Yes. Chlordiazepoxide metabolizes into nordiazepam and oxazepam, the same metabolites the standard BZO immunoassay panel is designed to detect, so a positive result reflects accurate detection rather than an interference error.
Is a Librium positive a false positive?
No. There is limited to no published evidence of chlordiazepoxide cross reacting with a benzodiazemine panel through an unrelated mechanism. It triggers the panel because it is metabolically a benzodiazepine, not because of an assay quirk.
Can a drug test tell the difference between Librium and Valium?
Not on the initial immunoassay screen, since both convert through nordiazepam. GC/MS or LC/MS confirmation testing can identify the specific parent drug and metabolite pattern present, which is the level of detail a medical review officer needs.
How long does a chlordiazepoxide taper stay detectable?
It varies by dose, duration of the taper, and individual metabolism, since the active metabolite nordiazepam clears slowly. There is no fixed number of days that applies to everyone, and a prescribing clinician is better positioned to discuss an individual timeline than a generic estimate.
What should someone in alcohol withdrawal treatment do if they are drug tested for work?
Disclose the prescription and treatment to the medical review officer and make sure the prescribing facility can confirm it if contacted. That documentation is what allows a benzodiazepine positive tied to legitimate treatment to be verified correctly.
Does a positive BZO result always come from Librium specifically?
No. The BZO panel reports a class level result. Diazepam, temazepam, and several other prescription and non prescription benzodiazepines can produce the same positive, which is why confirmation testing and MRO review exist.
Related reading: Benzodiazepine Drug Test: BZO Panel Detection Times and Gaps and Does Valium Show Up on a Drug Test? Diazepam and the Benzodiazepine Panel.
This article is general information about drug testing science and panel design. It is not medical or legal advice. Anyone with questions about a specific prescription, test result, or workplace policy should talk to their prescribing clinician, a medical review officer, or qualified counsel.
